Seres Therapeutics (MCRB) Tops Q3 EPS by 4c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $13.02 million versus the consensus estimate of $10.38 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Investing.com’s stocks of the week
• Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance